MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.470
+0.030 (2.08%)
At close: Jul 15, 2026, 4:00 PM EDT
1.470
0.00 (0.00%)
After-hours: Jul 15, 2026, 4:10 PM EDT
MAIA Biotechnology Employees
MAIA Biotechnology had 13 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,865,274
Market Cap
89.38M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 13 | 0 | - |
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | -5 | -27.78% |
| Dec 31, 2022 | 18 | 9 | 100.00% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Adicet Bio | 102 |
| Pelthos Therapeutics | 92 |
| Acrivon Therapeutics | 76 |
| Biomea Fusion | 40 |
| Cardiff Oncology | 31 |
| NeurAxis | 24 |
| LeonaBio | 19 |
| Cognition Therapeutics | 14 |
MAIA News
- 7 days ago - MAIA Biotechnology reports efficacy data from Phase 2 THIO-101 Part C expansion - TheFly
- 7 days ago - MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial - GlobeNewsWire
- 20 days ago - MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer - GlobeNewsWire
- 27 days ago - MAIA Biotechnology opens third clinical site in U.S. for Phase 2 THIO-101 trial - TheFly
- 27 days ago - MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University - GlobeNewsWire
- 5 weeks ago - MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial - GlobeNewsWire
- 5 weeks ago - MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial - TheFly
- 5 weeks ago - MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial - GlobeNewsWire